Related references
Note: Only part of the references are listed.The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay
Matthew Evans et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype
Julia R. Naso et al.
HISTOPATHOLOGY (2020)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino et al.
LANCET ONCOLOGY (2020)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
Jacqueline Aredo et al.
LUNG CANCER (2019)
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort
Yan Jin et al.
JOURNAL OF THORACIC DISEASE (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Etiology of Metabolic Syndrome and Dietary Intervention
Hang Xu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
Haipeng Xu et al.
ONCOTARGETS AND THERAPY (2019)
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer
Yuichi Saito et al.
JOURNAL OF THORACIC DISEASE (2019)
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer
Sarah E. Gradecki et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs An Interclone Evaluation by Differently Trained Pathologists
Enrico Munari et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients
Jeng-Sen Tseng et al.
JOURNAL OF IMMUNOTHERAPY (2018)
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Enrico Munari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 expression in lung adenocarcinoma harboring &ITEGFR&IT mutations or &ITALK&IT rearrangements
Yasuto Yoneshima et al.
LUNG CANCER (2018)
Role of immune-checkpoint inhibitors in lung cancer
Prantesh Jain et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
Olivier Bylicki et al.
TARGETED ONCOLOGY (2017)
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer
Yunjian Pan et al.
JOURNAL OF THORACIC DISEASE (2017)
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
Shaodong Hong et al.
ONCOIMMUNOLOGY (2016)
The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer
Frank C. Detterbeck et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
Tiffany G. Huynh et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
Jong-Mu Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review
Vicente Morales-Oyarvide et al.
CURRENT OPINION IN PULMONARY MEDICINE (2014)
Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome
Min Jae Cha et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2014)
Share Paper
